Comparative Pharmacology
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus ORETIC.
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs ORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
Amiloride: 6-9 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment, heart failure).
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Amiloride: 50% unchanged in urine, 40% in feces (biliary); Hydrochlorothiazide: >95% unchanged in urine.
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic